Archives of Neuroscience

Published by: Kowsar

Nature and History of Ebola Virus: An Overview

Muhammad Umair Majid 1 , Muhammad Sufyan Tahir 1 , Qurban Ali 1 , * , Abdul Qayyum Rao 1 , Bushra Rashid 1 , Arfan Ali 2 , Idrees Ahmad Nasir 1 and Tayyab Husnain 1
Authors Information
1 Center of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan
2 Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan
Article information
  • Archives of Neuroscience: July 01, 2016, 3 (3); e35027
  • Published Online: June 7, 2016
  • Article Type: Review Article
  • Received: November 29, 2015
  • Revised: January 13, 2016
  • Accepted: January 25, 2016
  • DOI: 10.5812/archneurosci.35027

To Cite: Majid M U, Tahir M S, Ali Q, Rao A Q, Rashid B, et al. Nature and History of Ebola Virus: An Overview, Arch Neurosci. 2016 ; 3(3):e35027. doi: 10.5812/archneurosci.35027.

Abstract
Copyright © 2016, Tehran University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Origin and Distribution
3. Hosts
4. Genome and Structure
5. EBOV Receptors and Entry Mechanism
6. Replication and Pathogenicity of Ebola Virus
7. Mode of Action
8. Disease and Symptoms
9. Epidemiology and Transmission of Ebola
10. Historical Outbreaks and the Studied Cases
11. Countries with Widespread Transmission and Current Scenario
12. Diagnostic Strategies
13. Clinical Implications or Applications
14. Disinfection
15. Vaccination and Medication
16. Prevention
17. Future Thrusts and Strategies
Footnote
References
  • 1. Taylor LH, Latham SM, Woolhouse ME. Risk factors for human disease emergence. Philos Trans R Soc Lond B Biol Sci. 2001; 356(1411): 983-9[DOI][PubMed]
  • 2. Rasheed A, Ullah S, Naeem S, Zubair M, Ahmad W, Hussain Z. Occurrence of HCV genotypes in different age groups of patients from Lahore, Pakistan. Advancements Life Sci. 2014; 1(2): 89-95
  • 3. Lennemann NJ, Rhein BA, Ndungo E, Chandran K, Qiu X, Maury W. Comprehensive functional analysis of N-linked glycans on Ebola virus GP1. MBio. 2014; 5(1)-13[DOI][PubMed]
  • 4. Drosten C, Kummerer BM, Schmitz H, Gunther S. Molecular diagnostics of viral hemorrhagic fevers. Antiviral Res. 2003; 57(1-2): 61-87[PubMed]
  • 5. Yaqoob A, Shehzad U, Ahmad Z, Naseer N, Bashir S. Effective treatment strategies against Ebola virus. Advancements Life Sci. 2015; 2(4): 176-82
  • 6. Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team. Bull World Health Organ. 1978; 56(2): 247-70[PubMed]
  • 7. Elliott LH, Kiley MP, McCormick JB. Descriptive analysis of Ebola virus proteins. Virology. 1985; 147(1): 169-76[PubMed]
  • 8. Miranda ME, Ksiazek TG, Retuya TJ, Khan AS, Sanchez A, Fulhorst CF, et al. Epidemiology of Ebola (subtype Reston) virus in the Philippines, 1996. J Infect Dis. 1999; 179 Suppl 1-9[DOI][PubMed]
  • 9. Miranda ME, Miranda NL. Reston ebolavirus in humans and animals in the Philippines: a review. J Infect Dis. 2011; 204 Suppl 3-60[DOI][PubMed]
  • 10. Mari Saez A, Weiss S, Nowak K, Lapeyre V, Zimmermann F, Dux A, et al. Investigating the zoonotic origin of the West African Ebola epidemic. EMBO Mol Med. 2015; 7(1): 17-23[DOI][PubMed]
  • 11. Beeching NJ, Fenech M, Houlihan CF. Ebola virus disease. BMJ. 2014; 349[DOI][PubMed]
  • 12. Leroy EM, Kumulungui B, Pourrut X, Rouquet P, Hassanin A, Yaba P, et al. Fruit bats as reservoirs of Ebola virus. Nature. 2005; 438(7068): 575-6[DOI][PubMed]
  • 13. Leroy EM, Rouquet P, Formenty P, Souquiere S, Kilbourne A, Froment JM, et al. Multiple Ebola virus transmission events and rapid decline of central African wildlife. Science. 2004; 303(5656): 387-90[DOI][PubMed]
  • 14. Ogawa H, Miyamoto H, Nakayama E, Yoshida R, Nakamura I, Sawa H, et al. Seroepidemiological Prevalence of Multiple Species of Filoviruses in Fruit Bats (Eidolon helvum) Migrating in Africa. J Infect Dis. 2015; 212 Suppl 2-8[DOI][PubMed]
  • 15. Kuhl A, Hoffmann M, Muller MA, Munster VJ, Gnirss K, Kiene M, et al. Comparative analysis of Ebola virus glycoprotein interactions with human and bat cells. J Infect Dis. 2011; 204 Suppl 3-9[DOI][PubMed]
  • 16. Taylor DJ, Leach RW, Bruenn J. Filoviruses are ancient and integrated into mammalian genomes. BMC Evol Biol. 2010; 10: 193[DOI][PubMed]
  • 17. Muhlberger E, Lotfering B, Klenk HD, Becker S. Three of the four nucleocapsid proteins of Marburg virus, NP, VP35, and L, are sufficient to mediate replication and transcription of Marburg virus-specific monocistronic minigenomes. J Virol. 1998; 72(11): 8756-64[PubMed]
  • 18. Muhlberger E, Weik M, Volchkov VE, Klenk HD, Becker S. Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems. J Virol. 1999; 73(3): 2333-42[PubMed]
  • 19. Timmins J, Scianimanico S, Schoehn G, Weissenhorn W. Vesicular release of ebola virus matrix protein VP40. Virology. 2001; 283(1): 1-6[DOI][PubMed]
  • 20. Noda T, Sagara H, Suzuki E, Takada A, Kida H, Kawaoka Y. Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol. 2002; 76(10): 4855-65[PubMed]
  • 21. Huang Y, Xu L, Sun Y, Nabel GJ. The assembly of ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein. Molecular Cell. 2002; 10(2): 307-16[DOI]
  • 22. Hoenen T, Jung S, Herwig A, Groseth A, Becker S. Both matrix proteins of Ebola virus contribute to the regulation of viral genome replication and transcription. Virology. 2010; 403(1): 56-66[DOI][PubMed]
  • 23. Chippaux JP. Outbreaks of Ebola virus disease in Africa: the beginnings of a tragic saga. J Venom Anim Toxins Incl Trop Dis. 2014; 20(1): 44[DOI][PubMed]
  • 24. Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB, et al. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA. 2002; 287(18): 2391-405[PubMed]
  • 25. Takada A, Watanabe S, Ito H, Okazaki K, Kida H, Kawaoka Y. Downregulation of beta1 integrins by Ebola virus glycoprotein: implication for virus entry. Virology. 2000; 278(1): 20-6[DOI][PubMed]
  • 26. Takada A, Fujioka K, Tsuiji M, Morikawa A, Higashi N, Ebihara H, et al. Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry. J Virol. 2004; 78(6): 2943-7[PubMed]
  • 27. Simmons G, Reeves JD, Grogan CC, Vandenberghe LH, Baribaud F, Whitbeck JC, et al. DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology. 2003; 305(1): 115-23[PubMed]
  • 28. Lin G, Simmons G, Pohlmann S, Baribaud F, Ni H, Leslie GJ, et al. Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR. J Virol. 2003; 77(2): 1337-46[PubMed]
  • 29. Kobinger GP, Leung A, Neufeld J, Richardson JS, Falzarano D, Smith G, et al. Replication, pathogenicity, shedding, and transmission of Zaire ebolavirus in pigs. J Infect Dis. 2011; 204(2): 200-8[DOI][PubMed]
  • 30. Carette JE, Raaben M, Wong AC, Herbert AS, Obernosterer G, Mulherkar N, et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature. 2011; 477(7364): 340-3[DOI][PubMed]
  • 31. Miller EH, Obernosterer G, Raaben M, Herbert AS, Deffieu MS, Krishnan A, et al. Ebola virus entry requires the host-programmed recognition of an intracellular receptor. EMBO J. 2012; 31(8): 1947-60[DOI][PubMed]
  • 32. Kondratowicz AS, Lennemann NJ, Sinn PL, Davey RA, Hunt CL, Moller-Tank S, et al. T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus. Proc Natl Acad Sci U S A. 2011; 108(20): 8426-31[DOI][PubMed]
  • 33. Shimojima M, Takada A, Ebihara H, Neumann G, Fujioka K, Irimura T, et al. Tyro3 family-mediated cell entry of Ebola and Marburg viruses. J Virol. 2006; 80(20): 10109-16[DOI][PubMed]
  • 34. Schornberg K, Matsuyama S, Kabsch K, Delos S, Bouton A, White J. Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J Virol. 2006; 80(8): 4174-8[DOI][PubMed]
  • 35. Takahashi K, Halfmann P, Oyama M, Kozuka-Hata H, Noda T, Kawaoka Y. DNA topoisomerase 1 facilitates the transcription and replication of the Ebola virus genome. J Virol. 2013; 87(16): 8862-9[DOI][PubMed]
  • 36. Empig CJ, Goldsmith MA. Association of the caveola vesicular system with cellular entry by filoviruses. J Virol. 2002; 76(10): 5266-70[PubMed]
  • 37. Wool-Lewis RJ, Bates P. Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines. J Virol. 1998; 72(4): 3155-60[PubMed]
  • 38. Feldmann H, Nichol ST, Klenk HD, Peters CJ, Sanchez A. Characterization of filoviruses based on differences in structure and antigenicity of the virion glycoprotein. Virology. 1994; 199(2): 469-73[DOI][PubMed]
  • 39. Volchkov VE, Feldmann H, Volchkova VA, Klenk HD. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc Natl Acad Sci U S A. 1998; 95(10): 5762-7[PubMed]
  • 40. Kaletsky RL, Simmons G, Bates P. Proteolysis of the Ebola virus glycoproteins enhances virus binding and infectivity. J Virol. 2007; 81(24): 13378-84[DOI][PubMed]
  • 41. Hood CL, Abraham J, Boyington JC, Leung K, Kwong PD, Nabel GJ. Biochemical and structural characterization of cathepsin L-processed Ebola virus glycoprotein: implications for viral entry and immunogenicity. J Virol. 2010; 84(6): 2972-82[DOI][PubMed]
  • 42. Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, Saphire EO. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature. 2008; 454(7201): 177-82[DOI][PubMed]
  • 43. Brecher M, Schornberg KL, Delos SE, Fusco ML, Saphire EO, White JM. Cathepsin cleavage potentiates the Ebola virus glycoprotein to undergo a subsequent fusion-relevant conformational change. J Virol. 2012; 86(1): 364-72[DOI][PubMed]
  • 44. Jeffers SA, Sanders DA, Sanchez A. Covalent modifications of the ebola virus glycoprotein. J Virol. 2002; 76(24): 12463-72[PubMed]
  • 45. Brindley MA, Hughes L, Ruiz A, McCray PJ, Sanchez A, Sanders DA, et al. Ebola virus glycoprotein 1: identification of residues important for binding and postbinding events. J Virol. 2007; 81(14): 7702-9[DOI][PubMed]
  • 46. Weissenhorn W, Carfi A, Lee KH, Skehel JJ, Wiley DC. Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol Cell. 1998; 2(5): 605-16[PubMed]
  • 47. Yang ZY, Duckers HJ, Sullivan NJ, Sanchez A, Nabel EG, Nabel GJ. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med. 2000; 6(8): 886-9[DOI][PubMed]
  • 48. Kondratowicz AS, Hunt CL, Davey RA, Cherry S, Maury WJ. AMP-activated protein kinase is required for the macropinocytic internalization of ebolavirus. J Virol. 2013; 87(2): 746-55[DOI][PubMed]
  • 49. Chandran K, Sullivan NJ, Felbor U, Whelan SP, Cunningham JM. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science. 2005; 308(5728): 1643-5[DOI][PubMed]
  • 50. Hartman AL, Towner JS, Nichol ST. Ebola and marburg hemorrhagic fever. Clin Lab Med. 2010; 30(1): 161-77[DOI][PubMed]
  • 51. Wauquier N, Becquart P, Padilla C, Baize S, Leroy EM. Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl Trop Dis. 2010; 4(10)[DOI][PubMed]
  • 52. Baize S, Leroy EM, Georges-Courbot MC, Capron M, Lansoud-Soukate J, Debre P, et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med. 1999; 5(4): 423-6[DOI][PubMed]
  • 53. Jahrling PB, Marty AM, Geisbert T. Viral hemorrhagic fevers. Medical Aspects of Biological Warfare . 2007; : 271-310
  • 54. Strickland G. Hunter's tropical medicine and emerging infectious diseases. 2000;
  • 55. Bausch DG, Towner JS, Dowell SF, Kaducu F, Lukwiya M, Sanchez A, et al. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis. 2007; 196 Suppl 2-7[DOI][PubMed]
  • 56. Pinzon JE, Wilson JM, Tucker CJ, Arthur R, Jahrling PB, Formenty P. Trigger events: enviroclimatic coupling of Ebola hemorrhagic fever outbreaks. Am J Trop Med Hyg. 2004; 71(5): 664-74[PubMed]
  • 57. Borchert M, Mutyaba I, Van Kerkhove MD, Lutwama J, Luwaga H, Bisoborwa G, et al. Ebola haemorrhagic fever outbreak in Masindi District, Uganda: outbreak description and lessons learned. BMC Infect Dis. 2011; 11: 357[DOI][PubMed]
  • 58. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet. 2011; 377(9768): 849-62[DOI][PubMed]
  • 59. Formenty P, Hatz C, Le Guenno B, Stoll A, Rogenmoser P, Widmer A. Human infection due to Ebola virus, subtype Cote d'Ivoire: clinical and biologic presentation. J Infect Dis. 1999; 179 Suppl 1-53[DOI][PubMed]
  • 60. Georges-Courbot MC, Lu CY, Lansoud-Soukate J, Leroy E, Baize S. Isolation and partial molecular characterisation of a strain of Ebola virus during a recent epidemic of viral haemorrhagic fever in Gabon. Lancet. 1997; 349(9046): 181[PubMed]
  • 61. Sanchez A, Ksiazek TG, Rollin PE, Miranda ME, Trappier SG, Khan AS, et al. Detection and molecular characterization of Ebola viruses causing disease in human and nonhuman primates. J Infect Dis. 1999; 179 Suppl 1-9[DOI][PubMed]
  • 62. Wamala JF, Lukwago L, Malimbo M, Nguku P, Yoti Z, Musenero M, et al. Ebola hemorrhagic fever associated with novel virus strain, Uganda, 2007-2008. Emerg Infect Dis. 2010; 16(7): 1087-92[DOI][PubMed]
  • 63. Maganga GD, Kapetshi J, Berthet N, Kebela Ilunga B, Kabange F, Mbala Kingebeni P, et al. Ebola virus disease in the Democratic Republic of Congo. N Engl J Med. 2014; 371(22): 2083-91[DOI][PubMed]
  • 64. Brown CS, Cropley IM. Ebola virus disease: where are we now and where do we go? Postgrad Med J. 2014; 90(1069): 610-2[DOI][PubMed]
  • 65. WHO Ebola Response Team . Ebola virus disease in West Africa--the first 9 months of the epidemic and forward projections. N Engl J Med. 2014; 371(16): 1481-95[DOI][PubMed]
  • 66. Geisbert TW, Daddario-DiCaprio KM, Williams KJ, Geisbert JB, Leung A, Feldmann F, et al. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol. 2008; 82(11): 5664-8[DOI][PubMed]
  • 67. Khan AS, Tshioko FK, Heymann DL, Le Guenno B, Nabeth P, Kerstiens B, et al. The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis. 1999; 179 Suppl 1-86[DOI][PubMed]
  • 68. Albarino CG, Shoemaker T, Khristova ML, Wamala JF, Muyembe JJ, Balinandi S, et al. Genomic analysis of filoviruses associated with four viral hemorrhagic fever outbreaks in Uganda and the Democratic Republic of the Congo in 2012. Virology. 2013; 442(2): 97-100[DOI][PubMed]
  • 69. Okware SI, Omaswa F, Talisuna A, Amandua J, Amone J, Onek P, et al. Managing Ebola from rural to urban slum settings: experiences from Uganda. Afr Health Sci. 2015; 15(1): 312-21[DOI][PubMed]
  • 70. Grard G, Biek R, Tamfum JJ, Fair J, Wolfe N, Formenty P, et al. Emergence of divergent Zaire ebola virus strains in Democratic Republic of the Congo in 2007 and 2008. J Infect Dis. 2011; 204 Suppl 3-84[DOI][PubMed]
  • 71. MacNeil A, Farnon EC, Wamala J, Okware S, Cannon DL, Reed Z, et al. Proportion of deaths and clinical features in Bundibugyo Ebola virus infection, Uganda. Emerg Infect Dis. 2010; 16(12): 1969-72[DOI][PubMed]
  • 72. Roddy P, Howard N, Van Kerkhove MD, Lutwama J, Wamala J, Yoti Z, et al. Clinical manifestations and case management of Ebola haemorrhagic fever caused by a newly identified virus strain, Bundibugyo, Uganda, 2007-2008. PLoS One. 2012; 7(12)[DOI][PubMed]
  • 73. Leroy EM, Epelboin A, Mondonge V, Pourrut X, Gonzalez JP, Muyembe-Tamfum JJ, et al. Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo, 2007. Vector Borne Zoonotic Dis. 2009; 9(6): 723-8[DOI][PubMed]
  • 74. Nkoghe D, Kone ML, Yada A, Leroy E. A limited outbreak of Ebola haemorrhagic fever in Etoumbi, Republic of Congo, 2005. Trans R Soc Trop Med Hyg. 2011; 105(8): 466-72[DOI][PubMed]
  • 75. Ng S, Basta NE, Cowling BJ. Association between temperature, humidity and ebolavirus disease outbreaks in Africa, 1976 to 2014. 2014;
  • 76. Rouquet P, Froment JM, Bermejo M, Kilbourn A, Karesh W, Reed P, et al. Wild animal mortality monitoring and human Ebola outbreaks, Gabon and Republic of Congo, 2001-2003. Emerg Infect Dis. 2005; 11(2): 283-90[DOI][PubMed]
  • 77. Leroy EM, Souquiere S, Rouquet P, Drevet D. Re-emergence of ebola haemorrhagic fever in Gabon. Lancet. 2002; 359(9307): 712[PubMed]
  • 78. Hutchinson KL, Rollin PE. Cytokine and chemokine expression in humans infected with Sudan Ebola virus. J Infect Dis. 2007; 196 Suppl 2-63[DOI][PubMed]
  • 79. Georges AJ, Leroy EM, Renaut AA, Benissan CT, Nabias RJ, Ngoc MT, et al. Ebola hemorrhagic fever outbreaks in Gabon, 1994-1997: epidemiologic and health control issues. J Infect Dis. 1999; 179 Suppl 1-75[DOI][PubMed]
  • 80. Dowell SF, Mukunu R, Ksiazek TG, Khan AS, Rollin PE, Peters CJ. Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis. 1999; 179 Suppl 1-91[DOI][PubMed]
  • 81. Baron RC, McCormick JB, Zubeir OA. Ebola virus disease in southern Sudan: hospital dissemination and intrafamilial spread. Bull World Health Organ. 1983; 61(6): 997-1003[PubMed]
  • 82. Heymann DL, Weisfeld JS, Webb PA, Johnson KM, Cairns T, Berquist H. Ebola hemorrhagic fever: Tandala, Zaire, 1977-1978. J Infect Dis. 1980; 142(3): 372-6[PubMed]
  • 83. Bres P. [The epidemic of Ebola haemorrhagic fever in Sudan and Zaire, 1976: introductory note]. Bull World Health Organ. 1978; 56(2): 245[PubMed]
  • 84. Geisbert TW, Jahrling PB. Differentiation of filoviruses by electron microscopy. Virus Res. 1995; 39(2-3): 129-50[PubMed]
  • 85. Ksiazek TG, Rollin PE, Jahrling PB, Johnson E, Dalgard DW, Peters CJ. Enzyme immunosorbent assay for Ebola virus antigens in tissues of infected primates. J Clin Microbiol. 1992; 30(4): 947-50[PubMed]
  • 86. Leroy EM, Baize S, Lu CY, McCormick JB, Georges AJ, Georges-Courbot MC, et al. Diagnosis of Ebola haemorrhagic fever by RT-PCR in an epidemic setting. J Med Virol. 2000; 60(4): 463-7[PubMed]
  • 87. Gibb TR, Norwood DAJ, Woollen N, Henchal EA. Development and evaluation of a fluorogenic 5' nuclease assay to detect and differentiate between Ebola virus subtypes Zaire and Sudan. J Clin Microbiol. 2001; 39(11): 4125-30[DOI][PubMed]
  • 88. Geisbert TW, Hensley LE. Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions. Expert Rev Mol Med. 2004; 6(20): 1-24[DOI][PubMed]
  • 89. Spickler AR. Ebolavirus and Marburgvirus Infections. 2004;
  • 90. Kamata T, Natesan M, Warfield K, Aman MJ, Ulrich RG. Determination of specific antibody responses to the six species of ebola and Marburg viruses by multiplexed protein microarrays. Clin Vaccine Immunol. 2014; 21(12): 1605-12[DOI][PubMed]
  • 91. Blaney JE, Wirblich C, Papaneri AB, Johnson RF, Myers CJ, Juelich TL, et al. Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. J Virol. 2011; 85(20): 10605-16[DOI][PubMed]
  • 92. Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, Bavari S. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis. 2007; 196 Suppl 2-7[DOI][PubMed]
  • 93. Swenson DL, Wang D, Luo M, Warfield KL, Woraratanadharm J, Holman DH, et al. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin Vaccine Immunol. 2008; 15(3): 460-7[DOI][PubMed]
  • 94. Jones SM, Feldmann H, Stroher U, Geisbert JB, Fernando L, Grolla A, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med. 2005; 11(7): 786-90[DOI][PubMed]
  • 95. Dixon MG, Schafer IJ, Centers for Disease Control and Prevention . Ebola viral disease outbreak--West Africa, 2014. MMWR Morb Mortal Wkly Rep. 2014; 63(25): 548-51[PubMed]
  • 96. Salvaggio MR, Baddley JW. Other viral bioweapons: Ebola and Marburg hemorrhagic fever. Dermatol Clin. 2004; 22(3): 291-302[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments